Filing Flows › Medifast (MED) › Q2 2026
Medifast (MED) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Medifast (MED) reported revenue of $76.4M for the second quarter 2026 (Q2 2026), -28% from a year earlier and +0.4% from the quarter before. Operating margin was -5.7%, net loss $3.1M (4.1% of revenue).
Medifast, Q2 2026: revenue $76.4M (-28% year over year), operating margin -5.7%, net loss $3.1M, operating cash flow $1.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $76.4M | +0.4% | -28% |
| Operating profit | −$4.3M | — | — |
| Net earnings | −$3.1M | — | -225% |
| Operating cash flow | $1.7M | +553% | — |
| Free cash flow | $728K | — | — |
What changed
Revenue was $76.4M in Q2 2026, down 28% year over year and roughly flat from the previous quarter.
Gross margin was 69.9%, down 2.7 points from Q2 2025. Operating costs exceeded revenue by $4.3M, an operating margin of -5.7%. Operating expenses fell 26% while revenue fell 28%. The quarter ended with a net loss of $3.1M, wider than the previous quarter's $2.1M loss. Non-operating items added $1.3M, -45% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $1.7M. Non-cash charges added back $3.4M of depreciation and amortization and $1.8M of share-based compensation. Working capital and other items used $467K. Capital expenditures of $1.0M left free cash flow of $728K.
Questions
What was Medifast's revenue in the second quarter 2026?
Medifast (MED) reported revenue of $76.4M for the second quarter 2026 (Q2 2026), -28% from a year earlier and +0.4% from the quarter before.
Was Medifast profitable in the second quarter 2026?
Operating loss was $4.3M (-5.7% of revenue) and net loss $3.1M.
Source: Medifast 10-Q on SEC EDGAR.